These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 26778079)

  • 1. The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.
    Xu MM; Pu Y; Zhang Y; Fu YX
    Trends Immunol; 2016 Feb; 37(2):141-153. PubMed ID: 26778079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.
    Wargo JA; Reuben A; Cooper ZA; Oh KS; Sullivan RJ
    Semin Oncol; 2015 Aug; 42(4):601-16. PubMed ID: 26320064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving synergistic combinations of targeted immunotherapies to combat cancer.
    Melero I; Berman DM; Aznar MA; Korman AJ; Pérez Gracia JL; Haanen J
    Nat Rev Cancer; 2015 Aug; 15(8):457-72. PubMed ID: 26205340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications.
    Esposito A; Criscitiello C; Curigliano G
    Curr Opin Oncol; 2015 Nov; 27(6):445-51. PubMed ID: 26447875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune based therapies in cancer.
    Krüger C; Greten TF; Korangy F
    Histol Histopathol; 2007 Jun; 22(6):687-96. PubMed ID: 17357098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
    Robert L; Ribas A; Hu-Lieskovan S
    Semin Immunol; 2016 Feb; 28(1):73-80. PubMed ID: 26861544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the tumor microenvironment by immunotherapy: part 2.
    Leibovici J; Itzhaki O; Huszar M; Sinai J
    Immunotherapy; 2011 Nov; 3(11):1385-408. PubMed ID: 22053888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy and immunotherapy: a beneficial liaison?
    Weichselbaum RR; Liang H; Deng L; Fu YX
    Nat Rev Clin Oncol; 2017 Jun; 14(6):365-379. PubMed ID: 28094262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors.
    Sinha D; Smith C; Khanna R
    Trends Mol Med; 2021 Jan; 27(1):75-90. PubMed ID: 33011081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical development of targeted and immune based anti-cancer therapies.
    Seebacher NA; Stacy AE; Porter GM; Merlot AM
    J Exp Clin Cancer Res; 2019 Apr; 38(1):156. PubMed ID: 30975211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.
    Chouaib S; Noman MZ; Kosmatopoulos K; Curran MA
    Oncogene; 2017 Jan; 36(4):439-445. PubMed ID: 27345407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic Cells and Cancer Immunity.
    Gardner A; Ruffell B
    Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy.
    Stakheyeva M; Riabov V; Mitrofanova I; Litviakov N; Choynzonov E; Cherdyntseva N; Kzhyshkowska J
    Curr Pharm Des; 2017; 23(32):4807-4826. PubMed ID: 28714406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy.
    Shahabi V; Postow MA; Tuck D; Wolchok JD
    Am J Clin Oncol; 2015 Feb; 38(1):90-7. PubMed ID: 25616204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer.
    Hughes PE; Caenepeel S; Wu LC
    Trends Immunol; 2016 Jul; 37(7):462-476. PubMed ID: 27216414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy.
    Sharma RK; Chheda ZS; Jala VR; Haribabu B
    Expert Rev Vaccines; 2015 Apr; 14(4):537-49. PubMed ID: 25482400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy.
    Michelle Xu M; Pu Y; Weichselbaum RR; Fu YX
    Oncogene; 2017 Feb; 36(5):585-592. PubMed ID: 27425593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.